Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 28, 2024Pediatric PulmonologyOpen Access

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data

View Full Paper
Ask AI
Bookmark
Share

Authors

DUDon S. UrquhartRoyal Hospital for ChildrenHDHeather DowleRoyal Hospital for ChildrenKMKellie Moffat

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Urquhart et al. (2024) studied this question.

synapsesocial.com/papers/68e77206b6db6435876e6ddbhttps://doi.org/10.1002/ppul.26938
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial2015 · 434 citations
  2. 2Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study2022 · 146 citations
  3. 3Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele2019 · 2,226 citations
  4. 4Normative multiple-breath washout data in school-aged children corrected for sensor error2022 · 47 citations
  5. 5Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis2004 · 261 citations